Is patients' insurance coverage associated with prescribing after hospitalization for severe, poorly controlled hypertension?

Journal of Clinical Hypertension

Volumn 10, Issue 9, 2008, Pages 684-691

  Dy, Sydney Morss ^a,b,c   Klag, Michael J ^a,b   Hunter Young, J ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LABETALOL; LISINOPRIL; METOPROLOL; NIFEDIPINE; PROPRANOLOL; VASODILATOR AGENT; VERAPAMIL; PRESCRIPTION DRUG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COST CONTROL; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG USE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SURVEY; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; BLOOD PRESSURE; COMPARATIVE STUDY; COST; CROSS-SECTIONAL STUDY; DRUG EFFECT; ECONOMICS; INSURANCE; MIDDLE AGED; PATHOPHYSIOLOGY; TEACHING HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; FEMALE; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; HYPERTENSION; INSURANCE COVERAGE; MALE; MIDDLE AGED; PRESCRIPTION DRUGS; SEVERITY OF ILLNESS INDEX;

EID: 58249084513     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00004.x     Document Type: Article

References (32)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(2):199-206.
2. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421-429.
3. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42(7):626-634.
4. Baker DW, Sudano JJ, Albert JM, et al. Lack of health insurance and decline in overall health in late middle age. N Engl J Med. 2001;345(15):1106-1112.
5. Tseng CW, Brook RH, Keeler E, et al. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-960.
6. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18(2):201-212.
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
8. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289(19):2560-2572.
9. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: Can better care cost less? JAMA. 2004;291(15):1850-1856.
10. Kasje WN, Timmer JW, Boendermaker PM, et al. Dutch GPs' perceptions: The influence of out-of-pocket costs on prescribing. Soc Sci Med. 2002;55(9):1571-1578.
11. Shea S, Misra D, Ehrlich MH, et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med. 1992;327(11):776-781.
12. Hill MN, Bone LR, Kim MT, et al. Barriers to hypertension care and control in young urban black men. Am J Hypertens. 1999;12(10, pt 1):951-958.
13. Gary TL, Bone LR, Hill MN, et al. Randomized controlled trial of the effects of nurse case manager and community health worker interventions on risk factors for diabetes-related complications in urban African Americans. Prev Med. 2003;37(1):23-32.
14. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med. 2000;160(18):2799-2803.
15. Drugs for hypertension. Med Lett Drugs Ther. 2001;43(1099):17-22.
16. Drugs for hypertension. Treat Guidel Med Lett. 2003;1(6):33-40.
17. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: The treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94(10):1782-1787.
18. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA. 2003;290(7):953-958.
19. Alexander GC, Casalino LP, Tseng CW, et al. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med. 2004;19(8):856-860.
20. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164(7):722-732.
21. Sawicki PT, McGauran N. Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care? Hypertension. 2006;48(1):1-7.
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
23. Ubel PA, Jepson C, Asch DA. Misperceptions about beta-blockers and diuretics: A national survey of primary care physicians. J Gen Intern Med. 2003;18(12):977-983.
24. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: Do patients with chronic illnesses tell their doctors? Arch Intern Med. 2004;164(16):1749-1755.
25. Lowet PF, Eisenberg JM. Can information on cost improve clinicians' behavior? Lessons from health care trials and management theory. Int J Technol Assess Health Care. 1997;13(4):553-561.
26. Schneeweiss S, Dormuth C, Grootendorst P, et al. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care. 2004;42(7):653-660.
27. Schneeweiss S, Soumerai SB, Glynn RJ, et al. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737-745.
28. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health Aff (Millwood). 2004; Suppl Web Exclusives: W4-455-W4-468.
29. Piette JD, Heisler M, Horne R, et al. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. Soc Sci Med. 2006;62(4):846-857.
30. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-337.
31. McWilliams JM, Zaslavsky AM, Meara E, et al. Impact of Medicare coverage on basic clinical services for previously uninsured adults. JAMA. 2003;290(6):757-764.
32. Drugs for hypertension. Treat Guidel Med Lett. 2005;3(34):39-48.